amitriptylinum viatris [amitriptylinum meda]
viatris healthcare limited - amitriptilinas - dengtos tabletės - 25 mg; 10 mg - amitriptyline
wakix
bioprojet pharma - pitolisant - narkolepsija - kiti nervų sistemos vaistai - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.
cerdelga
sanofi b.v. - teisingumas - gošė liga - kiti virškinimo trakto ir metabolizmo produktus, - cerdelga yra skirtas ilgalaikiam gydymui suaugusiems pacientams, sergantiems 1 tipo gošė liga (gd1), kurie yra nepakankamas cyp2d6 metabolizmas (pms), tarpinis vidutiniškas (ims) ar metabolizmas (eps).
orfarin
orion corporation - varfarinas - tabletės - 3 mg; 5 mg - warfarin
ozawade
bioprojet pharma - pitolisant - sleep apnea, obstructive - kiti nervų sistemos vaistai - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).
duodopa
abbvie sia - foslevodopa/foskarbidopa - infuzinis tirpalas - 240 mg/12 mg/ml - foslevodopa and decarboxylase inhibitor
aubagio
sanofi winthrop industrie - teriflunomide - išsėtinė sklerozė - selektyvūs imunosupresantai - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
haloperidol-richter
gedeon richter plc - haloperidolis - geriamieji lašai (tirpalas) - 2 mg/ml; 5 mg/ml; 1,5 mg; 5 mg - haloperidol
haloperidol decanoate–richter
gedeon richter plc - haloperidolio dekanoatas - injekcinis tirpalas - 70,52 mg/ml - haloperidol
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomide - išsėtinė sklerozė, grįžtamoji-pervedimo - imunosupresantai - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).